Immuno-Oncology Overview

Nov 23, 2015, 14:21 ET from Reportlinker

NEW YORK, Nov. 23, 2015 /PRNewswire/ -- This is an overview of the field of immuno-oncology and the various immuno-oncology classes Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions

Highlights

Datamonitor Healthcare anticipates that the PD-1/PD-L1 class will gain approvals for multiple tumor types, and that this class will be the most commercially successful immuno-oncology class over the next 10 years As monotherapies, PD-1 inhibitors will become the first-line treatment of choice in melanoma, and they are also likely to gain further approvals for a wide variety of cancers

CAR-T cell therapy early clinical results are extremely promising The leading CD19-targeted CAR-T treatments from Novartis, Juno, and Kite all provide response rates hovering around 90% for patients with multiply relapsed or refractory acute lymphoblastic leukemia

Expectations for cancer vaccines have diminished after multiple failures In theory, a cancer vaccine treatment should be able to strengthen the immune response against a cancer and help to prevent it from recurring In practice, a series of Phase III studies investigating cancer vaccines have failed to meet their primary endpoints, and the potential future role of this class has diminished with each trial failure

What's included in this report?

Three fully transcribed key opinion leader interviews

Coverage of the key immuno-oncology targets include key clinical trial results and a summary of deals related to that class

10-year sales forecasts are included for Yervoy, Opdivo, Keytruda, MEDI4736, and RG7446

Development focus map shows which targets are being investigated by each of the 63 companies with immuno-oncology drugs in development

Key questions answered:

What are the key immuno-oncology products in development?

What important clinical trial results have been reported for drugs in each immuno-oncology drug class?

What specific targets and therapy approaches are the developers in this field focusing on?

What factors could limit the commercial potential of immuno-oncology drugs in development?

What recent deals have taken place that are related to the field of immuno-oncology?

Read the full report: http://www.reportlinker.com/p03384787-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com